Categories: All postsInterviews

OneSoft Solutions is hitting its inflection point, CEO says

Dwayne Kushniruk
Oil and gas pipeline data company OneSoft Solutions (OneSoft Solutions Stock Quote, Chart TSXV:OSS) was featured this week at the 2019 Cantech Investment Conference. The company gave a presentation on Tuesday on its artificial intelligence-aided software to detect oil and gas pipeline failures, which has been gaining them clients as of late.

Started in 2015, the company now has a $61-million market cap and is about to break out in a big way in 2019, says Dwayne Kushniruk, CEO of the Edmonton-based OneSoft.

“We’re just now at the inflection point where we’re switching from R&D to revenue generation,” he says. “Last year, we had one client. We now have four, two of them are Fortune 500 and one of them is an industry supermajor. So our technology has been validated. It absolutely works.”

OneSoft started its pipeline data analysis project in 2015, and a year later they were chosen to participate in Microsoft’s first Accelerator program (they were one of nine out of 721 companies chosen worldwide).

The share price for OSS has had a good run over the past few months, rising more than 50 per cent since mid-September. Last week, the company reported its quarterly financials for the period ended November 30, 2018, generating revenue of $509,000 for the quarter, almost double that of a year prior, while reporting a consolidated net loss of $738,000 or $0.01 per share, up 17 per cent over the same period a year ago.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: oss
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

5 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

6 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

7 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

1 day ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

1 day ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

2 days ago